Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b randomized, double-blind placebo-controlled study of ENTR-601-44 non-ambulatory and ambulatory adult patients with DMD who are exon 44 skipping amenable

Next Previous
Trial Profile

A Phase 1b randomized, double-blind placebo-controlled study of ENTR-601-44 non-ambulatory and ambulatory adult patients with DMD who are exon 44 skipping amenable

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ENTR-601-44 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms ELEVATE-44-102

Most Recent Events

  • 26 Feb 2026 According to an Entrada Therapeutics media release, the Company plans to re-engage with the FDA to discuss increasing the planned doses in this clinical study. As such, the Company will provide an update on clinical study design and timing following interactions with the FDA.
  • 06 Oct 2025 According to an Entrada Therapeutics media release,The study will be conducted in the U.S. and is on track to initiate in the first half of 2026.
  • 27 Feb 2025 According to an Entrada Therapeutics media release, the company have submitted regulatory filings to initiate a global Phase 1/2 MAD clinical study of ENTR-601-45 ,also on a track to initiate ELEVATE-44-201 in the U.K. in Q2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top